drug discovery image concept

iStock

Fast-Tracking Drug Treatments for Viral Infections and Cancer

Using a new process, scientists can create new nucleoside analogs months earlier than with the previous method, paving the way for quicker drug discoveries

| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

Discovering antiviral and anticancer drugs will soon be faster and cheaper thanks to new research from Simon Fraser University chemist Robert Britton and his international team.

For the past 50 years, scientists have used manmade, synthetic, and nucleoside analogs to create drug therapies for diseases that involve the cellular division and/or the viral reproduction of infected cells. These diseases include hepatitis, herpes simplex, HIV, and cancer.

Lab manager academy logo

Get training in Lab Crisis Preparation and earn CEUs.

One of over 25 IACET-accredited courses in the Academy.

Certification logo

Lab Crisis Preparation course

But, says Britton, "That process has been intensive and challenging, limiting, and preventing the discovery of new drug therapies."

Now, using the new process, scientists can create new nucleoside analogs months earlier than with the previous method, paving the way for quicker drug discoveries. A paper on this research was published Aug. 7 in the journal Science.


Related Article: Informatics Approaches to In Silico Drug Discovery


"The reduction in time and cost of synthesis will vary, depending on the individual nucleoside analogue, but we have examples where we cut a 20-plus step synthesis, which takes several months to complete at the very least, down to three or four steps, which would only take a week or so," says Britton. "This is clearly a critical factor when it comes to treating newly evolved viruses like SARS-CoV-2 (COVID-19)."

The team shortened the process by replacing naturally occurring carbohydrates typically used for synthesizing these types of drugs.

"This entirely new approach builds in opportunities to diversify these drug scaffolds and should inspire new and unusual nucleoside analogue drug discoveries," says Britton.

Interested in life sciences?

Subscribe to our free Life Sciences Newsletter.

Is the form not loading? If you use an ad blocker or browser privacy features, try turning them off and refresh the page.

The team also replaced naturally derived chiral materials with achiral materials since they are generally cheaper and more versatile.

L.-C. Campeau, Merck's head of process chemistry and discovery process chemistry says, "One of our priorities is identifying problems limiting the speed of drug discovery and development, especially regarding synthesizing custom nucleoside analogs. We are very excited to collaborate with Professor Britton in establishing new methods to access this therapeutically important class of molecules."

- This press release was originally published on the SFU website

Loading Next Article...
Loading Next Article...

CURRENT ISSUE - January/February 2025

Energizing Leadership in Action

The science-backed behaviors that help leaders inspire thriving teams and organizations

Lab Manager January/February 2025 Cover Image